Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

TuHURA Biosciences, Inc. HURA

16 fiscal years on record · USD · FY2025 reported · SEC filings only
$0
$-30.1M
$-27.7M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

USD 0.00
Revenue, FY2025 · full 16-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.0 · Net income -30.1
-15M-30M
201020132016201920222025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
ROE
FY2025 · ROE -169.2%
50%100%150%-500%
201020172025
Three returns, three denominators.
Return on capital employedNot available: we don't have a clean operating profit figure for this period.

Each USD of equity lost 169 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -27.7
-10M-20M
201020172025
Net buybacks $ Dividends $
FY2023 · Dividends · · Net buybacks 24751.0
1000020000
2023

Total assetsUSD 27.4M
EquityUSD 20.9M
CashUSD 3.6M
Current ratio0.78×

Equity funds 77% of total assets.

The 16-year record

16 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
HURA, 16-year financial record
Metric 2025202420232022202120202019201820172016201520142013201220112010
Revenue $B0.00.00.0◌◌◌◌◌◌◌◌◌◌◌0.00.0
Operating income $B−0.0−0.00.0◌◌◌◌◌◌◌◌◌◌◌−0.0−0.0
EBITDA $B−0.0−0.00.0◌◌◌◌◌◌◌◌◌◌◌◌◌
Income tax $B0.00.00.0◌◌◌◌◌◌◌◌◌◌◌◌◌
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.00.00.00.0−0.00.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0◌◌◌◌◌◌◌◌◌◌◌◌◌
EPS, diluted $−0.63−1.21−2.47◌◌◌◌◌◌◌◌−0.110.00−0.18−0.160.00
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend————————————————
ROE %−169.2——−233.9−202.5−706.3−818.1−217.4185.4141.3—————−121.4
Shares out B0.060.010.01◌◌◌◌0.000.000.000.000.040.040.010.000.01

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 62 reconciliationsAUDITED

Reconciled in 16 of the 16 fiscal years we could check. Six checks were skipped: the balance sheet is not tagged before 2010. Three checks were skipped: EPS is not tagged before 2010.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inNevada
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2009

Share this section

Download image